18983288589(微信同号)
18983288589(微信同号)
18908392210(微信同号)
18980413049
2019-09-16
FDA-2019-D-3324
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
Not for implementation. Contains non-binding recommendations.
September 2019
This guidance is intended to clarify steps that owners of fish and fishery products, or their representatives, can take to segregate non-violative products from products adulterated with pathogens, unlawful animal drugs, scombrotoxin (histamine), and decomposition, to demonstrate compliance with the Federal Food, Drug, and Cosmetic Act (the FD&C Act). Specifically, this document provides guidance for reconditioning by:
This guidance does not supersede Compliance Policy Guide Sec. 160.700, Reconditioning of Foods Adulterated Under 402(a)(4) (Ref. 1). Nor does this guidance apply in situations where reconditioning is proposed by means other than segregation, such as by cooking or conversion to animal feed. Also, segregation alone may not be a reliable or acceptable means of reconditioning adulterated fish and fishery products that are adulterated under section 402(a)(4) of the FD&C Act.
Our guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe our current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in agency guidance documents means that something is suggested or recommended, but not required. Throughout this guidance the terms "you" and "your" refer to persons or establishments that are owners of fish and fishery products, or their representatives, interested in bringing adulterated products into compliance with the FD&C Act by means of segregating non-violative product from adulterated product.
(As used in this guidance, the term article refers to the quantity of food deemed by us to be adulterated.)
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2019-D-3324.
Pharma CMC2024-10-15
摩熵医药(原药融云)2024-08-21
数屿医械2024-06-24
数屿医械2024-06-13
数屿医械2024-05-30
摩熵医药(原药融云)2024-05-27
药事纵横2024-02-28
药通社2023-12-26
摩熵医药(原药融云)2023-12-13
药通社2023-06-25
2024-11-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-30
2024-10-30
2024-10-29
2024-10-28
2024-10-24
2024-10-24
2024-10-23
2024-10-23
2024-10-22
2024-10-21
2024-11-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-24
2024-10-22
2024-10-21
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-16
2024-10-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-30
2024-10-24
2024-10-22
2024-10-21
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-16
2024-10-15